Accelerated Stability Modeling for Peptides: a Case Study with Bacitracin.

Area of Science:

• Pharmaceutical Science
• Analytical Chemistry
• Physical Chemistry

Background:

• Peptide drug stability is crucial for therapeutic efficacy.
• Accelerated stability testing methods are needed to expedite drug development.
• Bacitracin, a peptide antibiotic, requires robust stability assessment.

Purpose of the Study:

• To apply the Accelerated Stability Assessment Program (ASAP) to a peptide active pharmaceutical ingredient (API) for the first time.
• To develop a predictive model for bacitracin stability under various temperature and humidity conditions.
• To validate the ASAP methodology for peptide drug stability assessment.

Main Methods:

• Bacitracin and its zinc complex were subjected to accelerated stress conditions (50–80°C, 0–63% RH).
• High-performance liquid chromatography (HPLC) and mass spectrometry (MS) were used to quantify bacitracin A and its degradants.
• Data were analyzed using a humidity-corrected Arrhenius equation and isoconversion approach.

Main Results:

• The ASAP model demonstrated good fit with low residuals across temperature and humidity.
• Predictions for bacitracin degradation and loss of active form aligned with longer-term stability data.
• The zinc complex of bacitracin showed comparable stability trends to the native form.

Conclusions:

• The Accelerated Stability Assessment Program (ASAP) is a validated approach for predicting the long-term stability of peptide drugs like bacitracin.
• This method significantly accelerates the determination of shelf-life for peptide APIs.
• ASAP provides a reliable tool for pharmaceutical development, reducing time and resources.